<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>29(1)</volume><submitter>Wang Q</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Post-COVID-19 pulmonary fibrosis is a significant long-term respiratory morbidity affecting patients' respiratory health. This exploratory study aims to investigate the incidence, clinical characteristics, and acute-phase risk factors for pulmonary fibrosis in COVID-19 patients. Additionally, it evaluates pulmonary function and chest CT outcomes to provide clinical evidence for the early identification of high-risk patients and the prevention of post-COVID-19 pulmonary fibrosis.&lt;h4>Methods&lt;/h4>We retrospectively analyzed 595 patients hospitalized for COVID-19 from January 2022 to July 2023. Patients were divided into fibrosis and nonfibrosis groups on the basis of imaging changes. Baseline data, including demographics, disease severity, laboratory indicators, and chest i</pubmed_abstract><journal>European journal of medical research</journal><pagination>585</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11657883</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Effects of acute-phase COVID-19-related indicators on pulmonary fibrosis and follow-up evaluation.</pubmed_title><pmcid>PMC11657883</pmcid><pubmed_authors>Wang Q</pubmed_authors><pubmed_authors>Xue P</pubmed_authors><pubmed_authors>Feng Y</pubmed_authors><pubmed_authors>Dong Z</pubmed_authors><pubmed_authors>Ma J</pubmed_authors><pubmed_authors>Zhou Y</pubmed_authors><pubmed_authors>Jing F</pubmed_authors></additional><is_claimable>false</is_claimable><name>Effects of acute-phase COVID-19-related indicators on pulmonary fibrosis and follow-up evaluation.</name><description>&lt;h4>Background&lt;/h4>Post-COVID-19 pulmonary fibrosis is a significant long-term respiratory morbidity affecting patients' respiratory health. This exploratory study aims to investigate the incidence, clinical characteristics, and acute-phase risk factors for pulmonary fibrosis in COVID-19 patients. Additionally, it evaluates pulmonary function and chest CT outcomes to provide clinical evidence for the early identification of high-risk patients and the prevention of post-COVID-19 pulmonary fibrosis.&lt;h4>Methods&lt;/h4>We retrospectively analyzed 595 patients hospitalized for COVID-19 from January 2022 to July 2023. Patients were divided into fibrosis and nonfibrosis groups on the basis of imaging changes. Baseline data, including demographics, disease severity, laboratory indicators, and chest i</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Dec</publication><modification>2025-04-27T00:32:02.386Z</modification><creation>2025-04-06T17:51:08.342Z</creation></dates><accession>S-EPMC11657883</accession><cross_references><pubmed>39696619</pubmed><doi>10.1186/s40001-024-02197-5</doi></cross_references></HashMap>